“In a Prospective, Multicenter Study, the 31-GEP Identified Patients at Increased Risk of Tumor Recurrence and Added Significant Prognostic Value to AJCC Staging”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s504, https://doi.org/10.25251/skin.8.supp.504.